Ogurtsova K, et al.. IDF diabetes atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017; 128:40–50.
Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol 3026; 12:73–81.
Perco P, Mayer G. Molecular, histological, and clinical phenotyping of diabetic nephropathy: valuable complementary information? Kidney Int 2018; 93:308–310.
Heerspink HJL, Perkovic V. Trial design innovations to accelerate therapeutic advances in chronic kidney disease: Moving from single trials to an ongoing platform. Clin J Am Soc Nephrol 2018; 13:946–948.
Heerspink HJL, List J, Perkovic V. New clinical trial designs for establishing drug efficacy and safety in a precision medicine era. Diabetes Obes Metab 2018; 20[Suppl 3]:14–18.
Mayer B, et al.. Predictive biomarkers for linking disease pathology and drug effect. Curr Pharm Des 2017; 23:29–54.
Heinzel A, et al.. Validation of plasma biomarker candidates for the prediction of eGFR decline in patients with type 2 diabetes. Diabetes Care 2018; 41:1947–1954.
Ahlqvist E, et al.. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol.
© 2021 American Society of Nephrology | All Rights Reserved
Powered by: PubFactory